Decisions
| Date | Case | Division | Action | Motion | Outcome | Summary |
|---|---|---|---|---|---|---|
| 2025-09-15 | UPC_APP_36556/2025 | Dusseldorf LD | Generic application | Procedural | Procedural only | The Düsseldorf Local Division denied Dolby International AB's application for court-ordered simultaneous interpretation (German to English) for the oral hearing, holding that a foreign claimant who chose German as the language of proceedings cannot compel the court to provide interpretation at court expense; Dolby could arrange its own interpretation under R. 109.2 RoP. |
| 2025-09-03 | UPC_APP_33210/2025 | Dusseldorf LD | Generic application | Preliminary injunction | PI granted | The Düsseldorf Local Division granted HP Development Company's application for a preliminary injunction against Andreas Rentmeister e.K. (Defendant 2) for alleged infringement of EP2826630 and EP3530469, including injunctions, information disclosure, and penalty payments, after the defendant failed to substantiate its objection to the provisional measures application. |
| 2025-05-02 | UPC_APP_20487/2025 | Dusseldorf LD | Application Rop 365 | Procedural | Settled | The Düsseldorf Local Division confirmed, under R. 365(1) RoP, a settlement reached between claimant Evac Oy and defendants 4–6 (VD Solutions GmbH, Yong Cao, and Katharina Kiran Singh Kang) in the patent infringement proceedings; the case against defendants 1–3 continues. |
| 2025-03-25 | UPC_APP_14382/2025 | Dusseldorf LD | Application Rop 365 | Procedural | Settled | The Düsseldorf Local Division confirmed a settlement between Nichia Corporation and Endrich Bauelemente Vertriebs GmbH in an infringement action concerning EP 2 323 178, and ordered reimbursement of 60% of court fees to the claimant as the settlement was reached during the written procedure. |
| 2025-03-04 | UPC_APP_4496/2025 | Dusseldorf LD | Generic application | Procedural | Procedural only | The Düsseldorf Local Division issued a procedural order in the GlaxoSmithKline v Pfizer RSV vaccine case (EP4183412), deciding to bifurcate by referring the counterclaim for revocation to the Milan Central Division while proceeding with the infringement action, and granting a one-month extension for Pfizer's rejoinder. |